XML 15 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Statements of Income and Comprehensive Income (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2018
Oct. 01, 2017
Sep. 30, 2018
Oct. 01, 2017
Revenues $ 20,330,000 $ 21,047,000 $ 66,263,000 $ 63,022,000
Cost of products sold 14,289,000 14,792,000 46,390,000 43,656,000
Gross profit 6,041,000 6,255,000 19,873,000 19,366,000
Operating expenses:        
Research and development 1,099,000 1,355,000 3,417,000 3,678,000
Selling, general and administrative 3,442,000 3,637,000 10,968,000 11,262,000
Total operating expenses 4,541,000 4,992,000 14,385,000 14,940,000
Operating income 1,500,000 1,263,000 5,488,000 4,426,000
Other expense (income):        
Interest and financing expense 13,000 38,000 67,000 147,000
Miscellaneous (34,000) 20,000 (40,000) 53,000
Income before income tax provision 1,521,000 1,205,000 5,461,000 4,226,000
Income Tax Provision 86,000 104,000 219,000 370,000
Net income 1,435,000 1,101,000 5,242,000 3,856,000
Net income attributable to non-controlling interest 27,000 3,000 57,000 8,000
Net income attributable to Ultralife Corporation 1,408,000 1,098,000 5,185,000 3,848,000
Other comprehensive (loss) income:        
Foreign currency translation adjustments (436,000) 440,000 (862,000) 1,193,000
Comprehensive (loss) income attributable to Ultralife Corporation $ 972,000 $ 1,538,000 $ 4,323,000 $ 5,041,000
Net income per share attributable to Ultralife common shareholders – basic (in dollars per share) $ 0.09 $ 0.07 $ 0.33 $ 0.25
Net income per share attributable to Ultralife common shareholders – diluted (in dollars per share) $ 0.09 $ 0.07 $ 0.32 $ 0.24
Weighted average shares outstanding – basic (in shares) 15,952 15,564 15,859 15,495
Potential common shares (in shares) 571 407 548 323
Weighted average shares outstanding - diluted (in shares) 16,523 15,971 16,407 15,818